Manufacturing Intelligence for CDMO Teams
Start each day with curated headlines on CDMO capacity, regulatory signals, and supply-chain moves — then read weekly deep dives that explain what changed structurally and how sponsors should adjust shortlists.
Feed: /api/seo/feed · Markdown mirrors: /posts/<slug>.md
- Daily newsCDMO Daily News — September 6, 2026
- Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Daily newsCDMO Daily News — September 4, 2026
- Cellipont Bioservices Advances Six Cell Therapy Programs to 2026 IND Submissions
- Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Daily newsCDMO Daily News — September 3, 2026
- Genprex Taps Andelyn Biosciences for AAV Diabetes Gene Therapy Scale-Up
- Lifecore Biomedical Wins Commercial Injectable Transfer; Seventh Late-Stage Program in 2026
- Daily newsCDMO Daily News — September 2, 2026
- Ennolys Expands Fermentation and Bioprocessing CDMO Services
- Daily newsCDMO Daily News — September 1, 2026
- Evonik Invests $108M in Vancouver Lipid-Drug Manufacturing Facility
- Ennolys Expands CDMO Services in Fermentation, DSP, and Drying
- Daily newsCDMO Daily News — August 29, 2026
- Evonik Invests $108M in Vancouver GMP Lipid Drug-Product Facility
- Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Daily newsCDMO Daily News — August 28, 2026
- 4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Daily newsCDMO Daily News — August 27, 2026
- 4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Daily newsCDMO Daily News — August 26, 2026
- Cambrex High Point Site Clears FDA, PMDA, TGA Inspections for API Manufacturing
- Integrated GMP Operating Models Reshape Outsourced Manufacturing for Emerging Biopharma
- Daily newsCDMO Daily News — August 25, 2026
- Halo Pharma Nears Activation of $45M Sterile Injectable Line
- Daily newsCDMO Daily News — August 22, 2026
- Halo Pharma Activates $45M Sterile Injectable Line in New Jersey
- Daily newsCDMO Daily News — August 21, 2026
- Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Expands ADC Platform
- Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- Deep diveFill finish drug product CDMO outsourcing capacity
Sterile fill-finish capacity has become the critical constraint for drug manufacturers in 2025–2026, with outsourcing hitting record levels as biologic approvals and GLP-1 demand surge faster than CDMOs can expand specialized infrastructure. Sponsors must now compete aggressively for limited slots at tier-one CDMOs while managing the risk
- Daily newsCDMO Daily News — August 20, 2026
- SK pharmteco Opens Small-Molecule and HPAPI Manufacturing Expansions in Ireland
- Cytovance Biologics Launches Standalone Analytical Services for Biologics Development
- Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Bolsters ADC Platform
- Genprex Partners with U.S. CDMO for AAV Diabetes Gene Therapy Scale-Up
- Daily newsCDMO Daily News — August 18, 2026
- WuXi XDC Achieves GMP Release for Singapore Bioconjugate Production Line
- Daily newsCDMO Daily News — August 15, 2026
- Cabaletta Bio Adds ElevateBio as Second CDMO Partner Alongside Lonza for Rese-cel
- NurExone Selects Made Scientific for Exclusive U.S. Exosome GMP Manufacturing
- Samsung Biologics Achieves 90-Day Dual-Site Tech Transfer for GMP Biologics Manufacturing
- Daily newsCDMO Daily News — August 12, 2026
- Cambrex Breaks Ground on $30M Milan R&D Facility; Iowa API Plant Engineering Complete
- Daily newsCDMO Daily News — August 11, 2026
- Transcenta Sells Hangzhou GMP Plant to WuXi Biologics for $26.2M
- Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal
- Daily newsCDMO Daily News — August 8, 2026
- CPC Scientific Passes FDA Pre-License Inspection for Hepcludex API Manufacturing
- Altruist Biologics Completes Commercial PPQ on 20,000L Bioreactors in Hangzhou
- Gland Pharma and Neuland Laboratories Launch Sterile API CDMO Partnership in India
- Porton Advanced Gains China NMPA Class C License for Commercial CGT Manufacturing
- Deep diveMitigating FDA Drug Shortages with Contract Manufacturing
CDMOs have evolved from peripheral vendors to essential infrastructure for preventing FDA drug shortages, with sponsors now prioritizing manufacturing partner quality and tech-transfer capability over raw capacity to ensure supply resilience. This structural shift reflects lessons from COVID-19 and positions outsourcing as a decentralized
- Daily newsCDMO Daily News — August 6, 2026
- AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity
- CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and Asia Peptide Capacity
- Altasciences Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing
- Piramal Pharma Solutions Opens Spray-Drying Suite for Peptide Formulation in India
- Taysha Secures Commercial Manufacturing with Catalent for Gene Therapy TSHA-102
- Daily newsCDMO Daily News — August 3, 2026
- CRAMSN COO: Strategic CDMO Model Requires Separate Operating Teams, Not One-Size-Fits-All Approach
- Daily newsCDMO Daily News — August 1, 2026
- AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha Therapies
- Resilience and Eli Lilly Expand Ohio Manufacturing Partnership With $750M Investment
- Deep diveFill-finish outsourcing: CDMOs meet soaring demand for high-quality services
Biopharma sponsors are rapidly outsourcing fill-finish operations to specialized CDMOs as injectable therapies dominate pipelines and regulatory burdens mount, with AI-powered process control and patient-centric delivery systems becoming key competitive differentiators in a market projected to nearly double by 2034.
- Daily newsCDMO Daily News — July 30, 2026
- Cellipont Bioservices Reaches 100 GMP Batch Releases at Texas Cell Therapy Facility
- Daily newsCDMO Daily News — July 29, 2026
- AsymBio Expands Shanghai Biologics R&D with New Eight-Story Facility
- Asymchem's Jilin Carbapenem API Facility Passes First FDA Pre-Approval Inspection
- Daily newsCDMO Daily News — July 28, 2026
- Laurus Labs CDMO Revenue Surges 67% on Small Molecule API Demand
- AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development
- Asymchem's Jilin Carbapenem API Facility Clears First FDA Pre-Approval Inspection
- Daily newsCDMO Daily News — July 24, 2026
- ImmuPharma Selects Thermo Fisher for Kapiglucagon Drug-Product CDMO Services
- SK pharmteco Advances AAV Gene Therapy to Phase III with 20 Clinical Batches for Genethon DMD Program
- Restore Vision Selects Forge Biologics for RV-001 AAV Gene Therapy Manufacturing
- Deep diveCDMO biologics capacity and manufacturing bottlenecks: navigating capacity constraints
Biologics manufacturing capacity lags demand by a structural margin, forcing pharma to prioritize CDMO partnership flexibility over technical credentials alone while emerging technologies like membrane-based processing and continuous manufacturing offer near-term relief without major capital investment. Policy reform and workforce develop
- Daily newsCDMO Daily News — July 19, 2026
- OXB Expands AAV Manufacturing with Plowshare Therapies Gene Therapy Deal
- Daily newsCDMO Daily News — July 17, 2026
- BriaCell Selects FUJIFILM Biotechnologies California for Bria-IMT Phase 3 and Commercial Manufacturing
- OXB Secures AAV Manufacturing Contract with Plowshare Therapies
- Merck Opens €25M BioReliance Testing Facility in Darmstadt, Germany
- Cytovance Biologics Adds Perfusion Capabilities to Upstream Process Development
- Deep diveBIOSECURE Act CDMO supply chain risk: 5-10% annual capacity tightening
BIOSECURE Act restrictions are triggering a genuine 5–10% annual capacity contraction among compliant CDMOs through 2026, forcing sponsors into costly supply-chain audits and premium pricing as they compete for scarce manufacturing slots with zero China exposure across their entire vendor networks.
- Daily newsCDMO Daily News — July 11, 2026
- FDA Proposes Streamlined Registration for Distributed Manufacturing and Foreign Drug Suppliers
- FDA FRAME Initiative Establishes Regulatory Framework for Advanced Manufacturing Technologies
- Daily newsCDMO Daily News — July 4, 2026
- FDA PreCheck Pilot Selects Seven Companies to Expand U.S. Drug Manufacturing Capacity
- Deep diveAPI CDMOs Navigate Geopolitical Risk: Dual Sourcing & Supply Resilience in 2026
The active pharmaceutical ingredient (API) manufacturing landscape is undergoing a structural realignment driven by geopolitical fragmentation and supply-chain vulnerability. As 2026 approaches, the traditional "make versus buy" calculus has fundamentally shifted. Pharmaceutical companies now weigh strategic control, risk tolerance, and regulatory…
- Daily newsCDMO Daily News — July 1, 2026
- AGC Biologics Expands US Fill-Finish via Pyramid Pharma Partnership
- Cytiva Doubles Logan, UT Liquid Media Capacity with New ADCF Facility
- Daily newsCDMO Daily News — June 24, 2026
- EMA Convenes AI in GMP Workshop to Shape Annex 22 Guidance on Adaptive Models
- Deep dive503B Outsourcing Facilities & FDA Drug Shortages: Can CDMOs Close the Supply Gap?
- Daily newsCDMO Daily News — June 15, 2026
- CCRM's OmniaBio Partners with Avectas to Advance Automated Cell Therapy Manufacturing
- Daily newsCDMO Daily News — June 11, 2026
- Scinai Completes Recipharm Israel Acquisition, Expands CDMO Platform to Two Sites
- Deep diveSterile Biologics Capacity Crunch: How to Secure CDMO Slots in 2026
- Daily newsCDMO Daily News — June 9, 2026
- Cell & Gene Therapy CDMOs Address Manufacturing Complexity and Capacity Gaps
- Single-Site Operations and Integrated Teams Reduce CDMO Partnership Risk
- Daily newsCDMO Daily News — June 6, 2026
- Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1
- Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility